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ABSTRACT
Most bladder cancer (BC) patients need life-long, invasive and expensive 
monitoring and treatment, making it a serious burden on the health system. Thus, 
there is a pressing need for an accurate test to assist diagnosis and surveillance of BC 
as an alternative to cystoscopy. Mutations in human TERT, FGFR3, PIK3CA, and RAS 
genes have been proposed as potential molecular markers in bladder tumor. Their 
concomitant presence in urine samples has not been fully explored.
We investigated a panel of mutations in DNA from exfoliated urinary cells of 255 
BC patients at diagnosis. Forty-one mutations in TERT, FGFR3, PIK3CA, and RAS were 
analyzed by SNaPshot assay in relation to clinical outcome. In 81 of these patients 
under surveillance, the same set of mutations was screened in additional 324 samples 
prospectively collected.
The most common mutations detected in urine at diagnosis were in the TERT 
promoter. In non-invasive BC, these mutations were related to high risk and grade 
(p<0.0001) as well as progression to muscle-invasive disease (p=0.01), whereas 
FGFR3 mutations were observed in low-grade BC (p=0.02) and patients with 
recurrences (p=0.05). Stronger associations were observed for combined TERT 
and FGFR3 mutations and number of recurrences (OR: 4.54 95% CI: 1.23-16.79, 
p=0.02). Analyses of the area under the curve for combinations of mutations detected 
at diagnosis and follow-up showed an accuracy of prediction of recurrence of 0.80 
(95% CI: 0.71-0.89).
Mutations in urine of BC patients may represent reliable biomarkers. In particular, 
TERT and FGFR3 mutations have a good accuracy of recurrence prediction.
INTRODUCTION
Bladder cancer (BC) is the seventh most frequently 
diagnosed malignancy worldwide in men [1] and the 
most common cancer of the urinary tract, with urothelial 
carcinoma being the dominant histology in more than 
90% of BC cases [2]. Approximately 75% of BC patients 
present with non-muscle-invasive BC (NMIBC), of 
which 70% are confined to the mucosa (Ta), 20% to the 
submucosa (T1), and 10% are carcinoma in situ (CIS) 
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[3]. According to current guidelines, these lesions are 
treated with transurethral resection of the bladder (TURB) 
followed by one intravesical instillation with mitomycin 
C. Patients with intermediate or high risk of progression 
to muscle-invasive cancer (MIBC) subsequently undergo 
several cycles of Bacillus Calmette-Guerin (BCG) 
instillations according to the guidelines of the European 
Association of Urology [4]. The remaining cases are 
MIBC for which the standard of care is radical cystectomy 
with pelvic lymph node dissection, with possible 
neoadjuvant or adjuvant chemotherapy [5].
MIBC cases exhibit a poor prognosis with a high 
risk of post-operative complications and an estimated 
five-year overall survival (OS) rate of 66% [5]. Although 
survival for NMIBC cases is over 90%, patients with 
these tumors are subject to high rates of recurrence (up 
to 78% at five years) and progression to muscle-invasive 
(up to 45% at five years) despite treatment [4]. For these 
patients, the goal is to detect and treat recurrences early 
in order to avoid the progression to MIBC. Currently, 
the only approach is a lifelong surveillance consisting 
of cystoscopy with or without biopsies and voided urine 
cytology [4, 5]. To improve the management of BC and 
at the same time decrease the costs, it is essential to find 
a non-invasive, highly sensitive, and specific molecular 
biomarker that allows detection of recurrences in urine.
BCs are derived from the urothelium involving, 
at least, two different genetic pathways and distinct 
progenitor cell types [6]. NMIBCs are characterized by 
frequent mutations in the fibroblast growth factor receptor 
3 (FGFR3) and three of the five human RAS genes 
such as Harvey rat sarcoma viral oncogene homolog 
(HRAS), Kirsten rat sarcoma viral oncogene homolog 
(KRAS), and neuroblastoma RAS viral (v-ras) oncogene 
homolog (NRAS) [7–9]. Also, a large proportion of 
human bladder tumors show alterations in some of 
the phosphatidylinositol 3-kinase (PI3K) pathway 
components; in particular, the phosphatidylinositol 
3-kinase catalytic subunit alpha (PIK3CA) gene [10] 
that is involved in controlling cell growth, survival, and 
proliferation and has been considered a promising target 
for cancer therapy [11, 12]. MIBC cases, which show a 
propensity to progress to local and distant metastasis, 
often contain defects in tumor suppressor genes [13–15]. 
The telomerase reverse transcriptase (TERT) promoter, an 
important element of telomerase expression, has emerged 
as a target of cancer-specific mutations. Originally 
described in melanoma, the mutations in human TERT 
promoter, mainly at -124 and -146 base pair positions 
from the ATG start site, have been shown to be common 
in certain tumor types including BC of all stages with 
mutation frequencies of up to 80% [16–20].
The choice of a urine-based assay to analyze BC 
genetic profiles poses a major advantage as urine is in 
contact with the tumor and can be collected in an easy, 
non-invasive and repeatable way. Urinary exfoliated 
cancer cells and secreted nucleic acids mirror bladder 
tumors along each step of cancer development [21]. In 
particular, the study of relevant mutations in urine has 
the potential to become a reliable tool for diagnostic/
prognostic purposes [22–24].
The aim of our study was to search simultaneously 
for mutations in TERT, FGFR3, PIK3CA, and RAS genes 
in the urinary exfoliated cells of a consecutive series of 
BC patients, both NMIBC and MIBC, and to evaluate 
their role as predictors of recurrence, progression, and 
survival. In a subgroup of 81 NMIBC patients, who have 
provided additional urine samples during their follow-up 
(for a total of 324 samples), mutations were repeatedly 
screened. To the best of our knowledge, this represents the 
largest number of mutations simultaneously investigated 
in urine, both at diagnosis and during clinical surveillance, 
for their association with BC.
RESULTS
Patient characteristics
Baseline patients’ characteristics are reported 
in Table 1. The cohort included 230 (90.2%) NMIBC 
patients most of whom were classified as high-risk (40%) 
and received adjuvant intravesical therapy (52.2%). 
Recurrence and progression were experienced by 38.3% 
and 4.3% of patients, respectively.
Twenty-five (9.8%) primary MIBC patients were 
also enrolled, 19 of which underwent radical cystectomy.
At a median follow-up of 5.83 years (range 1.21-
8.54 years), cancer-specific and overall mortality rates in 
primary NMIBC patients were 4.8% (n=11) and 13.9% 
(n=32), respectively, and in primary MIBC cases were 
36% (n=9) and 64% (n=16), respectively.
Mutation analysis in urinary exfoliated cells at 
diagnosis
Among the 230 urines obtained from the primary 
NMIBC cases, 159 samples had at least one mutation, 
thus sensitivity of tumor detection was 69%. TERT 
mutations were found in 119 (52%) urine samples while 
95 (41.6%) had a FGFR3 mutation. Sensitivity of the 
combination of both genes was 67%. Hence mutations 
in the RAS and PIK3CA genes only added 2% to the 
sensitivity (Table 2). The most common TERT mutations 
were the -124C>T (n=117) and -146C>T (n=19), with 
two subjects presenting both mutations simultaneously, 
while only five patients had mutations at -124C>A and 
-138_139CC>TT. The most common FGFR3 mutation 
was S249C (46%), followed by Y375C, K652M, 
K652E, and R248C (45% together). In 12 subjects, two 
simultaneous FGFR3 mutations were detected while 
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Table 1: Baseline characteristics of the patients with NMIBC or MIBC and information at follow-up
VARIABLES 
NMIBC
(n= 230)
MIBC
(n= 25)
N (%) N (%)
Age (years)   
 Mean ± SD 63.8 ± 8.0 64.7 ± 8.6
 Range 40.0-74.9 40.2-73.5
Smoking Status   
 Never 22 (9.6) 3 (12.0)
 Former 121 (52.6) 9 (36.0)
 Current 87 (37.8) 13 (52.0)
T stage   
 Tx 2 (0.9) -
 Ta 147 (63.9) -
 Tis 7 (3.0) -
 T1 74 (32.2) -
 T2 - 23 (92.0)
 T3+T4 - 2 (8.0)
Grading (1973)   
 G1 70 (30.4) -
 G2 99 (43.0) 1 (4.0)
 G3 61 (26.6) 24 (96.0)
Grading (2004)   
 Low grade 125 (54.3) -
 High grade 105 (45.7) 25 (100.0)
Tumor size (cm)   
 <3 168 (73.0) 7 (28.0)
 ≥3 62 (27) 18 (72.0)
Risk   
 Low-risk 60 (26.1) -
 Intermediate Risk 78 (33.9) -
 High-risk 92 (40.0) -
Recurrence   
 No 142 (61.7) -
 Yes 88 (38.3) -
Number of recurrences   
 1 56 (63.6) -
 2 21 (23.9) -
 ≥3 11 (12.5) -
(Continued )
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two subjects presented three mutations. Occurrence 
of more than one mutation for FGFR3 and TERT has 
been found before [22, 25] and is probably due to either 
tumor heterogeneity or the presence of multiple tumor 
clones in the bladder. Mutations in PIK3CA and RAS 
genes were detected in 13% and 4.8% of urine samples, 
respectively. For PIK3CA, the most frequent mutation 
was E545K (44%). Finally, for RAS genes, the majority 
of mutations were in KRAS G12V (25%). Distribution 
of mutations for each investigated gene is reported in 
Supplementary Figure S1.
The relationship between mutations observed 
in urine and clinical factors is reported for NMIBC in 
Table 2. TERT mutations significantly correlated with 
the presence of high-risk, high-grade tumors (for both 
p<0.0001) and progression to muscle-invasive disease 
(p=0.01). FGFR3 was associated with low-grade tumors 
(p=0.02) and event of recurrence/number of recurrences 
(p=0.05, p=0.04, respectively). PIK3CA mutations were 
more common in urine collected from low-grade tumors 
(p=0.03). Despite the low frequency of RAS mutations, 
an association was also seen between mutated RAS and 
no recurrence (p=0.04). The distribution of mutations at 
diagnosis with respect to the different genes and relation 
to tumor grading, risk, and recurrence are highlighted 
in Figure 1. As shown, TERT, FGFR3, and PIK3CA 
mutations overlap to some extent.
In Supplementary Table S1 the sensitivities of the 
assays for detection of muscle-invasive primary tumors 
is shown. In this group, 80% of the urine samples 
presented with a TERT mutation while other genes were 
less frequently mutated (<20%). We further investigated 
the possible association of the mutations and clinical 
parameters for MIBC patients. However, although there 
were some statistically significant relations, the numbers 
were too low to draw conclusions.
VARIABLES 
NMIBC
(n= 230)
MIBC
(n= 25)
N (%) N (%)
Progression to MIBC   
 No 220 (95.7) -
 Yes 10 (4.3) -
Therapy   
 No 110 (47.8) 22 (88.0)
 Yes 120 (52.2) 3 (12.0)
Type   
 BCG 67 (55.8) -
 Chemotherapy 53 (44.2) 3 (100.0)
Cystectomy   
 No 209 (90.9) 6 (24.0)
 Yes 21 (9.1) 19 (76.0)
Disease relapse after cystectomy   
 No 14 (66.7) 9 (47.4)
 Yes 7 (33.3) 10 (52.6)
Type   
 Local 3 (42.8) 3 (30.0)
 Distal 2 (28.6) 1 (10.0)
 Local+Distal 2 (28.6) 6 (60.0)
Status at follow-up   
 Alive 198 (86.1) 9 (36.0)
 Dead of all causes 32 (13.9) 16 (64.0)
 Dead of bladder cancer 11 (4.8) 9 (36.0)
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Table 2: Distributions of mutations of investigated genes in urinary exfoliated cells according to clinical and 
demographic characteristics of NMIBC patients
 Variables
TERT FGFR3 PIK3CA Ras
No 
Mutations
N (%)
≥1 
Mutations
N (%)
No 
Mutations
N (%)
≥1 
Mutations
N (%)
No 
Mutations
N (%)
≥1 
Mutations
N (%)
No 
Mutations
N (%)
≥1 
Mutations
N (%)
All patients 110 (48%) 119 (52%) 133 (58.4) 95 (41.6) 200 (87.0) 30 (13.0) 219 (95.2) 11 (4.8)
Age (years) 
Mean ± SD 63.1 ± 8.1 64.7± 7.9 63.7±8.3 63.9±7.6 64.1±7.9 61.5±8.4 63.7±8.0 64.4±8.0
 p= 0.13 p= 0.85 p= 0.10 p= 0.78
Smoking status 
 Never 42 (38.2%) 44 (37.0%) 50 (37.6%) 34 (35.8%) 76 (38.0%) 10 (33.3%) 81 (37.0%) 5 (45.5%)
 Former 59 (53.6%) 62 (52.1%) 70 (52.6) 52 (54.7%) 104 (52.0%) 18 (60.0%) 117 (53.4%) 5 (45.5%)
 Current 9 (8.2%) 13 (10.9%) 13 (9.8%) 9 (9.5%) 20 (10.0%) 2 (6.7) 21 (9.6%) 1 (9.0%)
 p= 0.78 p= 0.95 p= 0.68 p= 0.84
Grading (1973)  
 G1 48 (43.7%) 22 (18.5%) 35 (26.3%) 34 (35.8%) 57 (28.5%) 13 (43.3%) 66 (30.1%) 4 (36.4%)
 G2 47 (42.7%) 51 (42.9%) 50 (37.6%) 48 (50.5%) 86 (43.0%) 13 (43.3%) 94 (42.9%) 5 (45.4%)
 G3 15 (13.6%) 46 (38.6%) 48 (36.1%) 13 (13.7%) 57 (28.5%) 4 (13.4%) 59 (27.0%) 2 (18.2%)
 p <0.0001 p= 0.01 p= 0.13 p= 0.80
Grading (2004) 
 Low grade 75 (68.2%) 50 (42.0%) 63 (47.4%) 60 (63.2%) 103 (51.5%) 22 (73.3%) 117 (53.4%) 8 (72.7%)
 High grade 35 (31.8%) 69 (58.0%) 70 (52.6%) 35 (36.8%) 97 (48.5%) 8 (26.7%) 102 (46.6%) 3 (27.3%)
 p <0.0001 p= 0.02 p= 0.03 p= 0.21
Tumour size         
 <3cm 86 (78.2%) 81 (68.1%) 100 (75.2%) 66 (69.5%) 147 (73.5%) 21 (70.0%) 161 (73.5%) 7 (63.6%)
 ≥3cm 24 (21.8%) 38 (31.9%) 33 (24.8%) 29 (30.5%) 53 (26.5%) 9 (30.0%) 58 (26.5%) 4 (36.4%)
 p= 0.09 p= 0.34 p= 0.69 p= 0.47
Stage         
 Ta 82 (74.6%) 64 (53.8%) 78 (58.6%) 67 (70.5%) 126 (63.0%) 21 (70.0%) 139 (63.5%) 8 (72.7%)
 T1 24 (21.8%) 50 (42.0%) 48 (36.1%) 26 (27.4%) 65 (32.5%) 9 (30.0%) 71 (32.4%) 3 (27.3%)
 Tis 2 (1.8%) 5 (4.2%) 5 (3.8%) 2 (2.1%) 7 (3.5%) 0 7 (3.2%) 0
 Tx 2 (1.8%) 0 2 (1.5%) 0 2 (1.0%) 0 2 (0.9%) 0
 p= 0.01 p= 0.22 p= 0.66 p= 0.88
Risk         
 Low Risk 40 (36.4%) 20 (16.8%) 31 (23.3%) 28 (29.5%) 49 (24.5%) 11 (36.7%) 57 (26.0%) 3 (27.3%)
(Continued )
Oncotarget67440www.impactjournals.com/oncotarget
Overall and cancer survival
A higher percentage of patients who died either from 
any cause or cancer carried mutations in the analyzed 
genes at diagnosis (89.4% and 88.5%, respectively, data 
not shown). As presented in Supplementary Table S2, 
there was a significant association with OS in the adjusted 
model for FGFR3 mutations (p=0.04). Associations 
with OS were also noted with different combinations of 
genetic mutations. Figure 2 depicts Kaplan-Meier curves 
for all mutations combined (log-rank p=0.002) and 
TERT mutations only (log-rank p=0.003). No significant 
associations were observed between the mutations and 
cancer-specific survival.
Association of the presence of mutations at 
diagnosis and the occurrence of recurrences
In the NMIBC group, 88 subjects out of 230 (38%) 
experienced a recurrence during the clinical follow-up; 
among them, 56 recurred only once while the others 
manifested two or more recurrences. Of all patients who 
recurred, 28 (32%) had one gene mutated at diagnosis while 
34 (40%) presented two or more mutations. Thirty-one 
subjects had more than one recurrence (with a maximum 
of five) with 27 of them (87%) presenting one or more 
mutations. Among the remaining 142 non-recurring patients, 
23 (16%) had at least one mutation in a gene while 21 (15%) 
had more genes mutated simultaneously.
 Variables
TERT FGFR3 PIK3CA Ras
No 
Mutations
N (%)
≥1 
Mutations
N (%)
No 
Mutations
N (%)
≥1 
Mutations
N (%)
No 
Mutations
N (%)
≥1 
Mutations
N (%)
No 
Mutations
N (%)
≥1 
Mutations
N (%)
  Intermediate 
Risk
40 (36.4%) 37 (31.1%) 41 (30.8%) 36 (37.9%) 68 (34.0%) 10 (33.3%) 73 (33.4%) 5 (45.4%)
 High Risk 30 (27.2%) 62 (52.1) 61 (45.9%) 31 (32.6%) 83 (41.5%) 9 (30.0%) 89 (40.6%) 3 (27.3%)
 p <0.0001 p= 0.13 p= 0.31 p= 0.62
Recurrence         
 No 73 (66.4%) 69 (58.0%) 90 (67.7%) 52 (54.7%) 126 (63.0%) 16 (53.3%) 132 (60.3%) 10 (90.9%)
 Yes 37 (33.6%) 50 (42.0%) 43 (32.3%) 43 (45.3%) 74 (37.0%) 14 (46.7%) 87 (39.7%) 1 (9.1%)
 p= 0.19 p= 0.05 p= 0.30 p= 0.04
Number of recurrences 
 1 27 (73.0%) 28 (56.0%) 32 (74.4%) 23 (53.5%) 47 (63.5%) 9 (64.3%) 55 (63.2%) 1 (100.0%)
 ≥2 10 (27.0%) 22 (44.0%) 11 (25.6%) 20 (46.5%) 27 (36.5%) 5 (35.7%) 32 (36.8%) 0
 p= 0.10 p= 0.04 p= 0.96 p= 0.45
Progression to MIBC 
 No 109 (99.1%) 110 (92.4%) 125 (94.0%) 93 (97.9%) 191 (95.5%) 29 (96.7%) 209 (95.5%) 11 (100.0%)
 Yes 1 (0.9%) 9 (7.6%) 8 (6.0%) 2 (2.1%) 9 (4.5%) 1 (3.3%) 10 (4.5%) 0
 p= 0.01 p= 0.16 p= 0.77 p= 0.47
Survival at follow-up 
  Alive (or died 
due to causes 
other than 
BC)
109 (99.1%) 109 (91.6%) 124 (93.2%) 93 (97.9%) 190 (95.0%) 29 (96.7%) 209 (95.5%) 10 (90.9%)
 Dead 1 (0.9%) 10 (8.4%) 9 (6.8%) 2 (2.1%) 10 (5.0%) 1 (3.3%) 10 (4.5%) 1 (9.1%)
 p= 0.01 p= 0.11 p= 0.70 p= 0.49
Significant results in bold.
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Figure 2: Kaplan-Meier curve showing OS for A. subjects stratified for combined genes mutational status or B. TERT mutations 
alone.
Figure 1: Concurrent and mutually exclusive mutations in NMIBC patients at diagnosis A. and stratified according to grade 
B., risk C., or recurrence D.
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There was a consistently significant increase in the 
number of mutations in concomitance with an increased 
number of recurrences when genes were analyzed in 
combination or individually (OR: 2.05 95% CI: 1.05-
3.98, p=0.03). Although combining mutations in all 
genes significantly associated with recurrences, stronger 
associations were observed especially when mutations in 
the FGFR3 and TERT genes were combined (OR: 2.51 
95% CI: 1.26-5.00, p=0.01, Supplementary Table S3).
Detection of recurrences in NMIBC patients 
under surveillance
For 81 NMIBC patients, four additional urine 
samples were periodically collected over approximately 
three years after recruitment. There were no major 
differences in the investigated clinical parameters between 
this subgroup and the whole cohort. Within this subgroup, 
34 subjects underwent intravesical BCG treatment, 19 
underwent intravesical chemotherapy, while the remaining 
28 did not receive further treatment beyond TURB. Five 
of these patients died of causes other than BC during 
follow-up, all after recurrence and one after progression, 
and all of them presented mutations in their analyzed urine 
samples, either at diagnosis or follow-up.
In the first follow-up mutation analysis after 
diagnosis, the frequency of mutations dropped from 68% 
of subjects to 19%, still being mutations TERT mutation 
-124C>T the most frequent. The number of TERT 
mutations remained similar in the exfoliated cells from 
the collections that followed (data not shown).
Thirty-five subjects (43.2%) had a recurrence; of 
them, 27 (77%) presented one or more gene mutations. 
All 14 patients with multiple recurrences, except one, 
presented at least one mutation. Multivariate analyses 
(Table 3) confirmed the association between multiple 
gene mutations and the number of recurrences. Stronger 
associations were observed for TERT and FGFR3 
mutations combined with number of recurrences (OR: 
4.51, 95% CI: 1.27-16.06, p= 0.02 at diagnosis; OR: 4.54 
95% CI: 1.23-16.79, p= 0.02 at diagnosis, and follow-up). 
When FGFR3 and TERT gene mutations were observed 
in the diagnostic and a follow-up urine sample, the sum 
of their mutations detected at diagnosis and follow-up 
were more strongly associated either with the event of 
recurrence or with the number of recurrences than at 
diagnosis alone. Of those 29 patients with a mutation at 
diagnosis who did not recur, 23 (79.3%) did not present 
any further mutations over the four follow-up samplings. 
The distribution of mutations in FGFR3 and TERT in 
respect to recurrences in repeated samples is depicted by 
some examples in Supplementary Figure S2.
A prediction model for the presence of a recurrence 
was developed including age, smoking status, and risk of 
recurrence as covariates (Model A). Then, the mutational 
status as a predictor (Model B) and, finally, the mutational 
status during follow-up (Model C) were added each time 
to Model A. Considering all genes together, the area under 
curve (AUC) of the model increased from 0.72 (95% CI: 
0.61-0.83, Model A) to 0.75 (95% CI: 0.65-0.86, Model 
B) and to 0.78 (95% CI: 0.68-0.88, Model C). Using only 
the genes FGFR3 and TERT, model C reached an AUC of 
0.80 (95% CI: 0.71-0.89, model C). Receiver operating 
characteristic (ROC) curves for the different models are 
reported in Figure 3A and 3B, respectively, for all genes 
together or the FGFR3 and TERT combination. Adding 
the information of mutational status at diagnosis and 
follow-up, the predictive accuracy of the model was 8% 
higher when compared to that of the models usually used 
in clinical practice.
DISCUSSION
In the present study, we used urine analysis to 
diagnose primary and recurrent bladder tumors. We also 
looked at associations between mutations in urine at 
first diagnosis and clinical parameters. We selected six 
genes (FGFR3, PIK3CA, RAS family genes, and TERT 
promoter) and determined their mutation profile in 
urine samples of BC patients, first at diagnosis, prior to 
treatment, and secondly, for NMIBC patients, during their 
follow-up. The tests detected 70% of the first presentation 
NMIBC. Sensitivity for TERT and FGFR3 were 52% and 
42%, respectively. The distribution of mutations among 
genes is similar to other previous studies on tumor [22, 
26–29] and voided urine [22, 30, 31], although TERT 
mutations are lower [22, 32]. Two very recent studies have 
reported the same TERT mutation frequencies in urine of 
BC patients as us by different methodologies [26, 33]. 
In the small group of MIBC patients, sensitivity of the 
TERT assay was 80% while mutations in the other genes 
were less represented, in line with the distribution found 
in other studies [22]. Both TERT and FGFR3 mutations 
were related to clinical parameters: TERT mutations with 
high-risk, high-grade NMIBC, as well as with progression 
to MIBC and FGFR3 with low-grade tumors. Mutations 
in the FGFR3 gene have been previously found in 70% 
of the low-grade BC and are usually associated with a 
favorable prognosis [25, 34]. Patients with low-grade 
tumors are those at lower risk of progression, and the 
presence of an FGFR3 mutation has been associated with 
such behavior earlier [34, 35]. For TERT, mutations in 
urine were not previously observed in association with 
clinical parameters.
The same set of mutations was analyzed in 
exfoliated cells of samples collected from NMIBC patients 
during clinical surveillance. To our knowledge, this is the 
largest series of mutation analyses in multiple genes in 
repeated observations over time (for an overall number 
of 405 analyses). As expected, after the removal of the 
primary tumors with TURB and subsequent intravesical 
therapy, the number of patients with mutations in urinary 
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Figure 3: A. AUC for a set of BC risk factors (age, smoking status, and risk of recurrence, model A) and the same set of factors and 
mutational status of all genes at diagnosis (model B), and at diagnosis plus follow-up (model C). B. AUC for the same models but 
considering the mutational status of TERT and FGFR3 genes only.
Table 3: Mutations in repeated urine samples collected during follow-up in the subgroup of NMIBC patients (n= 81) 
in association with event(s) of recurrence
Genes 
At diagnosis At diagnosis +follow-up
Recurrence yes/no  Number of recurrences  Recurrence yes/no  
Number of 
recurrences  
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
All genes combined         
 1 gene mutated 1.71 (0.48-6.09) 0.41 1.91 (0.56-6.52) 0.30 0.99 (0.19-5.14) 0.99 1.02 (0.21-4.83) 0.98
 2 or more 3.19 (0.90-11.28) 0.07 4.11 (1.23-13.69) 0.02 3.16 (0.81-12.23) 0.10 3.80 (1.06-13.58) 0.04
TERT+FGFR3+PIK3CA         
 1 gene mutated 1.78 (0.52-6.15) 0.36 1.98 (0.60-1.26) 0.26 2.02 (0.44-9.29) 0.37 1.87 (0.45-7.72) 0.39
 2 or more 3.30 (0.90-12.11) 0.07 4.31 (1.26-14.76) 0.02 3.40 (0.85-13.63) 0.08 4.07 (1.11-14.84) 0.03
TERT+FGFR3+Ras         
 1 gene mutated 1.86 (0.55-6.35) 0.32 2.07 (0.63-6.73) 0.23 0.86 (0.17-4.40) 0.86 0.92 (0.20-4.31) 0.91
 2 or more 3.17 (0.864-11.63) 0.08 4.21 (1.23-14.35) 0.02 3.51 (0.89-13.77) 0.07 4.13 (1.15-14.84) 0.03
TERT+FGFR3         
 1 gene mutated 1.91 (0.57-6.37) 0.29 2.11 (0.66-6.73) 0.21 1.75 (0.39-7.89) 0.47 1.67 (0.41-6.86) 0.48
 2 or more 3.32 (0.86-12.86) 0.08 4.51 (1.27-16.06) 0.02 3.87 (0.94-15.87) 0.06 4.54 (1.23-16.79) 0.02
TERT 2.42 (0.79-7.39) 0.12 3.01 (1.06-8.59) 0.04 1.91 (1.13-3.22) 0.01 1.65 (1.14-2.39) 0.01
FGFR3 2.01 (0.72-5.61) 0.18 2.27(0.86-6.02) 0.10 1.89 (1.04-3.46) 0.04 1.54 (1.05-2.26) 0.02
PIK3CA 1.30 (0.33-5.14) 0.71 1.35 (0.39-4.76) 0.64 1.36 (0.68-2.77) 0.38 1.28 (0.75-2.21) 0.37
Ras 1.59 (0.08-29.76) 0.76 1.28(0.099-22.05) 0.78 1.56 (0.52-4.70) 0.43 1.38 (0.52-3.67) 0.52
Adjusted for age, smoking status, grade, stage and therapy. Significant results in bold.
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cells was considerably lower. Considering the potential 
of FGFR3 and TERT mutations at diagnosis and during 
follow-up for the prediction of recurrences, we explored if 
their implementation in clinical practice could improve the 
risk models currently used by urologists [4]. According to 
our results, the analysis of mutational status could improve 
the recurrence risk as measured by the EORTC risk tables 
with 8%. Similar findings were observed for FGFR3 
only in repeated urine samples collected over three 
years by Zuiverloon and colleagues [30]. We detected an 
association between the presence of multiple mutations 
and the number of recurrences, in particular, when TERT 
and FGFR3 mutations were combined. Even though TERT 
promoter mutations were more frequent than FGFR3 ones, 
the alterations at the two loci occurred together more 
frequently than per chance.
Considering the importance of detecting recurrences 
in patients with a low grade NMIBC, we have repeated 
analyses only in those patients belonging to this category. 
Interestingly, the frequency of mutations detected 
(combining all genes or considering them individually) 
and the associations previously described remained fairly 
similar to the whole set of NMIBC patients at diagnosis, 
or in the subset of those who provided multiple urine 
samples over time. In particular, in this last category, 
subjects with multiple recurrences were all mutated. This 
is particularly important considering that low grade tumors 
will experience more recurrences (as we also observed in 
our study population, i.e. 46% vs. 38%) and in routine 
investigations, like cytology, have a lower sensitivity in 
comparison to high-grade ones.
We are aware that the present study is affected by 
some limitations. First, there are inherent problems with 
urinary testing. As volume and stage/grade of BC can 
vary vastly, DNA testing must be able to deal with a small 
amount of exfoliated cells in urine. This is particularly true 
in post-diagnostic repeated sample collections, where the 
primary tumor has been removed and treatments may have 
occurred. In this respect, preliminary experiments were 
performed to investigate the sensitivity of the mutation 
detection assay by single nucleotide primer extension 
(SNaPshot) sequencing. Serial dilutions of samples at 
increasing concentrations of DNA from a healthy subject 
and a human cell line derived from a transitional cell 
carcinoma of the renal pelvis (UM-UC-14) were tested to 
identify the optimal concentration. The SNaPshot assay 
has proven to be an extremely sensitive technique able 
to detect even 1% of mutant alleles in a given sample, 
either with pre-amplification or without (data not shown). 
Moreover, in this study, no pre-amplification of the 
DNA of the samples was necessary. Urine represents a 
very dynamic fluid, and its composition can be affected 
by fluid status, renal disease, infection, and urinary 
tract instrumentation posing a disadvantage for the 
identification of a good marker. However, gene-based 
urinary biomarkers are more sensitive and specific as they 
detect cancer-related changes which are less likely to be 
affected by inflammatory and other benign conditions 
compared with protein-based detection [36].
From the point of view of the study design, repeated 
samplings of the subgroup of patients were performed not 
always in concomitance with the detection of a recurrence. 
Thus, we could not detect the presence of a mutation 
before or simultaneously with an event of recurrence and 
establish a clear relationship. Finally, our study is also 
limited since it is based on males only. BC is almost three 
times more common in men than in women; therefore, it 
is relatively simple to collect male patients. Although most 
likely some differences exist between genders for mutation 
detection and clinical outcomes [37, 38], we were unable 
to explore this. However, performing the assay only on 
men greatly reduced the variability.
Nevertheless, several strengths of this study must 
also be acknowledged: amongst them, the prospective 
design, the large number of samples analyzed, and the 
possibility of analyzing the mutational status of patients 
during follow-up. The heterogeneity of the population 
enrolled might be seen as a drawback, but in our opinion it 
reflects the complexity of BC, strengthening our findings. 
In addition, the analyses of all mutations were performed 
simultaneously by multiplexing the reactions. This is a 
very useful approach to screen a vast number of mutations 
at once, allowing us to save the biological material 
and always using the same experimental conditions at 
relatively low costs [12]. Moreover, urine is in direct 
contact with BC and sediment cells collected from voided 
samples are an ideal source of DNA because they are 
readily available, and the sampling is not invasive [39].
Most patients diagnosed with BC have NMIBC 
(75%) that are amenable to TURB and have a good five-
year survival rate (80-90%). However, 70% of subjects 
will have at least one recurrence within five years, and 
some will even recur after 15 years of surveillance. 
Although most NMIBC patients have recurrences of low-
stage and grade, progression to MIBC is observed in 10-
20%, leading to an entirely different scenario characterized 
by a worse prognosis despite radical treatments. The high 
recurrence rate and risk of progression to MI disease 
necessitates the frequent monitoring of NMIBC patients 
by performing periodic endoscopic procedures, with huge 
costs for the health system and discomfort for patients 
themselves [40–42]. To address this issue, in the era of 
the so-called “liquid biopsies”, research is focusing on 
the identification of molecular markers associated with 
the presence of BC [43, 44]. The ultimate goal would 
be to develop a urine-based biomarker to reduce the 
cystoscopy frequency and improve the patients' quality 
of life without jeopardizing their safety. Such tests should 
be easy-to-perform, reproducible, and simple to interpret. 
In this respect, from our study the panel of investigated 
gene mutations in voided urine samples may have the 
potential to be helpful in the diagnosis and surveillance of 
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BC patients. In particular, mutations in the TERT promoter 
and FGFR3 are the most frequently detected, with rates 
comparable to those of other studies and reflecting the 
situation in primary tumor tissue. Larger prospective 
studies from international consortia will provide the 
adequate study population size, including specific 
subgroups of patients with specific features of this cancer, 
to investigate the promising markers emerging. It can be 
expected that combinations of different molecular and 
histopathological biomarkers will be introduced into the 
clinical setting in the near future [45].
MATERIALS AND METHODS
Study population
The study population included 255 newly diagnosed, 
histologically confirmed cases of BC recruited at Città della 
Salute e della Scienza Hospital, Turin (Italy), between 2006 
and 2012. All subjects were men aged 40–75 years, living 
in the Turin metropolitan area that signed an informed 
consent form. Clinical and socio-demographic information 
were collected from all patients. Staging and grading were 
performed by expert uropathologists according to the 
tumor-node-metastases (TNM) 2002 classification and 
both the 1973 and 2004 World Health Organization (WHO) 
classifications. Patients were classified according to current 
European Organization for Research and Treatment of 
Cancer (EORTC) risk tables [46]. Recurrence was defined 
as the occurrence of any CIS and/or papillary Ta-T1 
tumor during follow-up, whereas the finding of T>1 was 
considered as progression. Progression for MIBC patients 
was defined as the presence of a local, distal or local-
distal extravesical disease. Causes of death were retrieved 
from local demographic offices and death certificates. All 
treatments were recorded. At 3-months follow-up, urine 
cytology and cystoscopy with TUR of all visible lesions 
and a biopsy mapping when appropriate were undertaken. 
Successively, follow-up was scheduled as per European 
Association of Urology (EAU) guidelines [5]. Subjects 
were defined as former smokers if they had quitted smoking 
≥1 year before the enrollment. This study was performed 
according to the principles of the Declaration of Helsinki 
and in agreement with ethical requirements. An internal 
ethical review board at Human Genetics Foundation of Turin 
(HuGeF committee/17-11-2011) approved the study.
Urine sample collection and DNA isolation from 
exfoliated cells
All subjects recruited in the study provided a urine 
sample at the time of diagnosis before any treatment. 
A subgroup of patients (n=81) under surveillance 
after diagnosis provided additional urine samples, 
approximately every six months from the recruitment, 
for a total of four collections. Freshly voided urine 
(10-100 mL) was collected before cystoscopy and stored 
at 4°C until their processing. Cells were pelleted by 
centrifugation for 10 minutes at 1,500 rpm and washed 
twice with 10 mL phosphate buffered saline (PBS). Finally, 
the cell pellet was stored at −80°C until DNA isolation. 
DNA was extracted using the QIAamp DNA Mini Kit 
(Qiagen) according to the manufacturer's protocol. 
DNA concentration was measured with Quant-iT High-
Sensitivity DNA Assay Kit (Life Technologies), and all 
samples were diluted to a fixed concentration of 5 ng/μl.
Mutation analyses
The mutation assays were performed as described by 
van Oers and colleagues [47]. Briefly, we performed three 
multiplex polymerase chain reactions (PCR) of the exons 
containing the most common mutations in the genes of 
interest. Each multiplex PCR reaction was performed in a 
total volume of 10 μl containing KAPA2G Robust HotStart 
ReadyMix 2X (KAPA Biosystems), 0.5 μl of the appropriate 
primer combination, and 5 ng of genomic DNA as template. 
Thermal cycling conditions consisted of initial denaturation 
at 95°C for 3 minutes, followed by 40 cycles each consisting 
of 95°C for 15 seconds, 55°C for 15 seconds, and 72°C 
for 20 seconds. The final elongation step was 72°C for 10 
minutes. Unincorporated primers and deoxynucleotide 
triphosphates were removed from PCR products by addition 
of 2 units of Exonuclease I (ExoI) and 1.5 units of Shrimp 
Alkaline Phosphatase (SAP, USB Corporation) at 37°C for 
60 minutes and 72°C for 15 minutes.
PCR products were subsequently analyzed for 
mutations using probes for each of the possible mutation 
sites and SNaPshot Multiplex Kit (Life Technologies). 
The mutation detection reactions were performed in a total 
volume of 10 μl containing 2.5 μl of SNaPshot Multiplex 
Ready Reaction Mix, 2 μl of BigDye Sequencing buffer, 1 
μl of probe mix, and 1 μl of SAP/ExoI treated PCR product. 
Extension reactions consisting of 35 cycles of denaturation 
at 96°C for 10 seconds and annealing/extension at 58.5°C 
for 40 seconds were performed in a thermal cycler. After 
extension, the excess of labelled dideoxynucleotide 
triphosphates was removed by treatment with 1 unit of SAP 
at 37°C for 60 minutes and 72°C for 15 minutes. Extended 
primers were denatured at 95°C for 4 minutes and separated 
by capillary electrophoresis on an automatic sequencer ABI 
PRISM 3130 XL Genetic Analyzer (Life Technologies). 
The presence or absence of a mutation was indicated by the 
fluorescent label on the incorporated nucleotide. Data were 
analyzed using GeneScan Analysis Software version 3.7 
(Life Technologies) and GeneMarker Software version 2.6 
(SoftGenetics LLC).
The first multiplex assay identifies simultaneously 
seven PIK3CA hotspot mutations (E542K, E545A, 
E545G, E545K, E545Q, H1047R and H1047L) and four 
TERT mutations (-124C>T (G>A), -124C>A (G>T), 
-138_139CC>TT (GG>AA) and -146C>T (G>A)). A 
second multiplex PCR detects the most frequent FGFR3 
mutations in three regions that comprise the following 
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codon mutations: R248C and S249C (exon 7); G372C, 
S373C, Y375C, G382R, A393E (exon 10); and K652M, 
K652T, K652E, K652Q (exon 15). Somatic mutations in 
the HRAS, KRAS and NRAS genes in BC affect codons 
12, 13 and 61. To facilitate detection of RAS mutations, 
we used a multiplex RAS mutation assay that screens for 
19 mutations simultaneously, representing 96% of all 
possibly known mutations in the three RAS genes [12].
Statistical analysis
Descriptive statistics of the baseline characteristics 
of the patients were reported using means and percentages, 
for NMIBC and MIBC separately.
The relationships between mutational status and 
clinical-demographic characteristics of patients were 
analyzed by T-test, Chi-square test, and Fisher exact test.
Follow-up time was considered time from diagnosis 
to death or loss of follow-up, depending on which came 
first. In the OS analysis all deaths were considered as 
events; in the cancer survival analysis, the events were 
only deaths of cancer. Kaplan-Meier plots were used to 
estimate the probability of overall and cancer survival 
according to the mutational status at diagnosis (log-rank 
test was performed to compare the curves).
Univariate logistic regression models were used 
considering the different clinical and demographic 
factors as predictors. The models were estimated for each 
outcome of interest, to identify the confounders to be 
included in the subsequent multivariate analysis.
A logistic regression model was fitted to estimate 
the odds ratio (OR) of recurrence comparing the several 
categories of mutational status for each gene and the genes 
combined. An ordered logistic regression model was also 
applied to estimate the impact of mutational status on the 
number of recurrences (0, 1, ≥2). In both analyses two 
different models were used: one unadjusted, and another 
adjusted for age, smoking status, stage, grade and therapy.
Finally, different prediction models for recurrence 
were built: 1) a model including age, smoking status, 
and risk of recurrence as predictors (Model A); 2) Model 
A with the additional predictor “mutational status at 
diagnosis” (Model B); and 3) Model A with the additional 
predictor “mutational status at diagnosis and follow-up” 
(Model C). ROC curves were plotted and AUC were 
calculated for each model to evaluate their performance 
prediction (range between 0.5 -random discrimination- 
and 1.0 -perfect discrimination-).
All analyses were performed using STATA version 
13 (StataCorp, LP).
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